Stock Screener App

Frei -

Installieren

3.99

3.16% -0.13

after-market

Handel nachbörslich: 3.95 -0.04 -1.00%

Kyverna Therapeutics Inc (KYTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten

Kyverna stock plunges 28% amid data update on lead drug - MSN

H.C. Wainwright cuts Kyverna stock price target by 14%, keeps Neutral stance - Investing.com

Kyverna stock maintains Neutral rating as analyst revises outlook amid higher costs - Investing.com

Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright - MarketBeat

Kyverna Therapeutics Announces New Patient Data Highlighting Pot - GuruFocus.com

What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings? - Defense World

institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop - Yahoo Finance

Wells Fargo & Company Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $24.00 - Defense World

Kyverna's CAR T-Cell Therapy Shows Promising Results in Lupus Nephritis Treatment | KYTX Stock News - StockTitan

Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Kyverna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - StreetInsider.com

(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat

(KYTX) Trading Report - Stock Traders Daily

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat

Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors | KYTX Stock News - StockTitan

Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey

(KYTX) Technical Data - Stock Traders Daily

500: Something went wrong - Investing.com

JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK

7 Best Nano Cap Stocks To Invest In - Insider Monkey

The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News

Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat

Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com

Down rounds don’t aid post-IPO performance - BioCentury

JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha

Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa

Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat

Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex

Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN

MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat

Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Bank of New York Mellon Corp Purchases Shares of 55,790 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLC - Defense World

Great Point Partners LLC Increases Stock Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

A Tale of Resilience: Kyverna Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle

XTX Topco Ltd Acquires Shares of 83,286 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

ECTRIMS 2024: Driving a fast CAR on the MS road and beyond - BioWorld Online

INCY

$70.39

0.93%

SMMT

$18.42

1.07%

MRNA

$38.25

3.55%

UTHR

$367.36

0.83%

BGNE

$194.56

0.15%

BNTX

$108.23

5.96%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters